The UK is on track to surpass its target of reducing commercial clinical trial set-up times to 150 days, with new data showing timelines have fallen to an average of 122 days — down from 169 days over the same period last year.
Backed by over £137 million in investment, the improvements reflect expanded research infrastructure, increased trial set-up capacity, and the establishment of 35 commercial research delivery centres across the UK.
While the impact is already evident in faster access to medicines and vaccines, the reforms are also significant for the in vitro diagnostics (IVD) sector. Accelerated trial timelines and increased study volume are expected to support more rapid validation and adoption of diagnostic technologies, including those used in stratified and precision medicine.
The UK has also reported a rise in global and European first patient enrolments, reinforcing its position as a leading destination for early-stage clinical research — with clear implications for companies developing innovative diagnostics alongside therapeutics.
